Spinal Muscular Atrophy clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not accepting new patients
This expanded access program (EAP) will provide access to risdiplam for eligible participants with Type 1 or Type 2 spinal muscular atrophy (SMA) before it is commercially available in the United States for the indication of SMA.
Fresno, California and other locations